Min-yi Cheng

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial.

Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 23, 2026

Development and validation of a multivariable risk model based on clinicopathological characteristics, mammography, and MRI imaging features for predicting axillary lymph node metastasis in patients with upgraded ductal carcinoma in situ.

Development and validation of a multivariable risk model based on clinicopathological characteristics, mammography, and MRI imaging features for predicting axillary lymph node metastasis in patients with upgraded ductal carcinoma in situ.

Journal: Gland surgery

Published: February 27, 2025

Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer.

Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer.

Journal: International journal of cancer

Published: August 27, 2023

Multifactor artificial intelligence model assists axillary lymph node surgery in breast cancer after neoadjuvant chemotherapy: multicenter retrospective cohort study.

Multifactor artificial intelligence model assists axillary lymph node surgery in breast cancer after neoadjuvant chemotherapy: multicenter retrospective cohort study.

Journal: International journal of surgery (London, England)

Published: April 20, 2023

Case report: solitary splenic metastasis occurring 19 months after primary treatment for occult breast cancer.

Case report: solitary splenic metastasis occurring 19 months after primary treatment for occult breast cancer.

Journal: Frontiers in oncology

Published: May 31, 2022

Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis.

Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis.

Journal: Breast (Edinburgh, Scotland)

Published: April 07, 2022

MicroRNA-132 promotes atherosclerosis by inducing mitochondrial oxidative stressmediated ferroptosis

MicroRNA-132 promotes atherosclerosis by inducing mitochondrial oxidative stressmediated ferroptosis

Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University

Published: March 07, 2022

Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis.

Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis.

Journal: Therapeutic advances in medical oncology

Published: November 03, 2021

Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures.

Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures.

Journal: Frontiers in molecular biosciences

Published: August 16, 2021

Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.

Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.

Journal: International journal of cancer

Published: June 09, 2021

Effects of dexmedetomidine doses on postoperative cognitive dysfunction and serum β- amyloid and cytokine levels in elderly patients after spine surgery: a randomized controlled trial

Effects of dexmedetomidine doses on postoperative cognitive dysfunction and serum β- amyloid and cytokine levels in elderly patients after spine surgery: a randomized controlled trial

Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University

Published: May 08, 2021

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials.

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials.

Journal: Breast (Edinburgh, Scotland)

Published: April 26, 2021

Showing 1-12 of 19

Last Updated: 09/26/2026